To enhance the therapeutic index of allogeneic hematopoietic SCT (HSCT), we immunized 10 HLA-matched sibling donors before stem cell collection with recipient-derived clonal myeloma Ig, idiotype (Id), as a tumor antigen, conjugated with keyhole limpet hemocyanin (KLH). Vaccinations were safe in donors and recipients. Donor-derived KLH-and Id-specific humoral and central and effector memory T-cell responses were detectable by day 30 after HSCT and were boosted by post-transplant vaccinations at 3 months in most recipients. One patient died before booster vaccinations. Specifically, after completing treatment, 8/9 myeloma recipients had persistent Id-specific immune responses and 5/9 had improvement in disease status. Although regulatory T cells increased after vaccination, they did not impact immune responses. At a median potential follow-up period of 74 months, 6 patients are alive, the 10 patients have a median PFS of 28.5 months and median OS has not been reached. Our results provide proof of principle that neoantigen and tumor antigen-specific humoral and cellular immunity could be safely induced in HSCT donors and passively transferred to recipients. This general strategy may be used to reduce relapse of malignancies and augment protection against infections after allogeneic HSCT.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) can eradicate hematologic malignancies through a combination of cytotoxic therapy and non-specific, immune-mediated effects of the allograft. [1] [2] [3] However, relapse remains a significant cause of treatment failure 4 and novel strategies are necessary to enhance the graftversus-tumor effect. Here, we immunized HSCT donors with a patient-derived tumor antigens with the goal of inducing antitumor immunity in the donors before HSC collection and passively transferring the immunity to recipients by HSCT. As most tumor antigens are self-antigens and vaccination with selfantigens may potentially induce autoimmunity, the use of a tumor-specific antigen is necessary for this approach to safely administer the vaccine to donors.
The clonal Ig produced by multiple myeloma (MM) cells has unique amino-acid sequences within the variable regions, termed idiotype (Id), that are distinct from normal Igs and therefore can serve as tumor-specific antigens for therapeutic vaccination. 5, 6 Active immunization with tumor-derived Id conjugated to a carrier, keyhole limpet hemocyanin (KLH) and administered together with GM-CSF as an adjuvant was found to be highly immunogenic 7, 8 and was recently shown to improve clinical outcome in follicular lymphoma patients in a randomized phase III trial. 9 However, the immunogenicity of Id vaccines in MM patients was disappointing, possibly due to self-tolerance and/or the immunosuppressed state of the patients resulting from therapy or the disease. [10] [11] [12] Vaccination of HSCT donors with a healthy immune system may potentially circumvent the barriers for active immunotherapy against tumors in recipients. 13, 14 In a limited number of MM patients undergoing allogeneic or syngeneic BMT, immunization of their respective donors with MM Id was safe and induced Id-specific humoral and cellular immunity. [15] [16] [17] The current study is distinct from our prior study by virtue of the following: (1) our prior study did not permit demonstration of transfer of vaccine-induced immunity to either KLH or Id, because the prior protocol design included pretransplant vaccination of the recipients (as well as the donors); [15] [16] [17] [18] (2) PBSC grafts may contain up to 10 times more lymphocytes than BM grafts and may result in more rapid donor lymphoid engraftment [19] [20] [21] and enhance the transfer of humoral and cellular immunity. Thus, the current study uses blood stem cells as the transfer element (instead of marrow); and (3) the current study uses a reduced intensity cytotoxic regimen (instead of myeloablation). 22 The scientific hypotheses tested in the current study of 10 donor-recipient pairs were: (1) that cellular immunity to a tumor antigen could be transferred directly from donor to recipient and (2) that donor-derived immunity could be boosted by MM recipient vaccination post-transplantation.
MATERIALS AND METHODS Subjects
Patients were X18 years of age, had IgG or IgA MM, a sibling that matched at 6/6 or 5/6 HLA antigens, adequate organ function and an M-protein concentration in plasma that was at least 70% of the total Ig of the corresponding isotype at study entry. After plasmapheresis for vaccine generation, patients were required to achieve at least a PR following conventional chemotherapy. The protocol was approved by the National Cancer Institute Institutional Review Board, and informed written consent was obtained from all patients and donors.
Treatment
While recipients were receiving conventional chemotherapy with etoposide, prednisone, VCR, CY, doxorubicin and fludarabine (EPOCH-F), a novel salvage regimen for MM before reduced-intensity allogeneic HSCT, 22 donors were immunized with three subcutaneous injections of Id-KLH þ GM-CSF vaccine at 10, 8 and 4 weeks before hematopoietic stem cell donation ( Figure 1 ). Approximately 3-4 weeks after the final immunization, donors received filgrastim (10 mg/kg/day) subcutaneously for hematopoietic stem cell mobilization, and starting on day 5, donors underwent daily aphereses until a minimum of 3 Â 10 6 CD34 þ cells/kg-recipient weight were obtained and cryopreserved. MM patients received a reduced-intensity conditioning regimen consisting of fludarabine and CY as previously described. 22 GVHD prophylaxis consisted of CYA for 180 days plus MTX (5 mg/m 2 ) on days þ 1, þ 3, þ 6 and þ 11 post-transplant. MM patients were vaccinated with three subcutaneous injections of Id-KLH þ GM-CSF at 3, 4 and 6 months post-transplant. Responses were evaluated using the European Group for Blood and Marrow Transplantation criteria available at the time this study was performed. 23 Vaccine formulation and immune assays Details on these are provided in Supplementary Methods.
Statistical analysis
A paired t-test or Wilcoxon signed-rank test was used to evaluate differences in immune responses or Foxp3 þ T cells between different time points. OS and PFS were determined by the Kaplan-Meier method. All P values are two-tailed.
RESULTS

Safety in donors
Ten MM patients and their respective HLA-matched sibling donors were enrolled in this study ( (Figures 2a and b; Supplementary Figures 1 A,B) . In the recipients, anti-KLH antibody responses were detected as early as 30 days post transplant in all nine patients assessed. Like the donors, the anti-KLH antibody responses in the recipients were of both IgM and IgG isotypes and increased significantly after post- (Table 1) had evidence of transfer of Id-specific immunity (R2, R3, R8 and R10; R9 was not evaluable). Together, these results suggest that like humoral immune responses, anti-KLH and anti-Id cellular immune responses were induced by vaccination in the donors and were passively transferred by HSCT to all eight recipients that were assessed. Furthermore, the transferred cellular immune responses were boosted by post-transplant immunizations in the recipients.
Effector and central memory T cells were induced by vaccination
Using an intracellular cytokine assay, we confirmed and further characterized the T-cell origin of the cytokine responses above. We confirmed that KLH-specific CD4 þ T cells were significantly higher in frequency in postvaccine PBMC compared with prevaccine PBMC in 9/9 donors assessed (Po0.05; Figures 5a and b; Supplementary Figure 2A ). KLH-specific CD4 þ T cells could be detected 90 days post transplant in 8/8 recipients assessed and could be transferred from the donor to the recipient (Supplementary Figure 2B) . Moreover, they increased further after post-transplant immunizations in six recipients (Figures 5c and d ; Supplementary Figure 2A) . The KLH-specific CD4 þ T cells were of both effector (CD27 þ / À CD62L À ) and central (CD27 þ CD62L þ ) memory phenotype in both donor-recipient pairs analyzed (Supplementary Figure 2C) .
Regulatory T cells (Tregs) in donors and recipients
To determine whether Tregs were induced by vaccination, we assessed the number of Foxp3 þ T cells by flow cytometry and Epitest assay. 24 The absolute number of Tregs increased significantly in 9/10 donors after the first vaccination as compared with prevaccine levels (D2-D10: Po0.01, paired t-test; Figure 6a ). However, Tregs declined to baseline levels after the second and third vaccinations (data not shown). Tregs also increased significantly in 7/8 recipients after the three posttransplant immunizations as compared to determination at 90-100 days post transplant (Po0.05, paired t-test; Figure 6b ). The change in Treg numbers showed similar trend when their numbers were estimated using two different techniques, flow (Figures 2c,d,f,h, 3b, 4c,d , and Supplementary Figures 1C,D,F) . These findings, taken together with chimerism studies showing that the T cells were 100% donor origin by day 30 and strong evidence of concurrent immunity to KLH, a neoantigen to which the transplant recipients had no prior exposure, strongly suggest that vaccine-induced tumor antigen immunity can be passively transferred to the recipients and is demonstrable very early after HSCT. Remarkably, the immune responses against both KLH and Id were observed while patients were on immunosuppressive GVHD prophylaxis. Finally, the detection of both antigen-specific effector and central memory T cells suggests that vaccinating donors might result in both immediate and long-lasting immunity in recipients.
We noted improvement in disease status in 5/9 patients who were evaluable at 100 days after HSCT (Table 1 ). Owing to the limited sample size, it is not possible to draw definitive conclusions about correlation between immune responses and clinical outcomes. Nevertheless, we found that improvement in disease post HSCT correlated with transfer of Id-specific immunity in all four patients that were assessable. Evidence of autoimmunity was not detected in the donors or recipients. Long-term survival lasting beyond 57 months was observed in 6/7 patients who did not die of transplant-related complications (Table 1) . Future randomized studies are warranted to determine clinical efficacy of donor immunization.
Nonetheless, our results may have implications for improving the therapeutic index of allogeneic HSCT. First, donor immunization may be used as a general strategy to enhance the graftversus-tumor effect in MM and other malignancies for which defined tumor-specific antigens exist. Second, vaccinating donors against infectious pathogens may be a potential strategy for prophylaxis against complications of early and late infections in the recipients. Indeed, enhanced antibody titers against infectious disease antigens were demonstrated in transplant recipients receiving hematopoietic grafts from donors immunized with infectious disease vaccines. [25] [26] [27] [28] [29] [30] However, these studies did not formally demonstrate transfer of vaccine-induced immunity, because they used recall antigens, and cellular immunity was Transfer of tumor immunity from transplant donors M Foglietta et al not determined. Furthermore, passive transfer of preexisting virusspecific T-cell immunity from unimmunized HSCT donors to recipients was shown to be inefficient. 31, 32 Compared with adoptive transfer of donor-derived ex vivo expanded viral antigen-specific T cells, 33, 34 active immunization of the donors may be more appealing and potentially more beneficial because of the ease of administering the vaccine and induction of both humoral and cellular immunity.
The KLH in our vaccine formulation also served as an internal control to assess the immunocompetency of donors and recipients. Heterogeneity was observed for both KLH-and Idspecific immune responses in donors and recipients. Overall, though, the magnitude of the humoral and cellular immune responses to KLH was substantially higher than Id-specific immune responses in both donors and recipients, as might be expected for an exogenous neoantigen ( Figures 2-4 and Supplementary  Figure 1) . These results also suggest that although myeloma Id is considered to be a tumor-specific antigen, its immunogenicity in healthy donors might be limited by mechanisms of self-tolerance due to the presence of shared epitopes between the tumor Id and IFNγ  IL4  IL5  IL10  IL13   R7   IL2  TNFα  GM-CSF   IFNγ  IL4  IL5  IL10  IL13   R6   IL2  TNFα  GM-CSF   IFNγ  IL4  IL5  IL10  IL13   R8   IL2  TNFα  GM-CSF   IFNγ  IL4  IL5  IL10  IL13   R10   IL2  TNFα  GM-CSF   IFNγ  IL4  IL5  IL10  IL13   R9   IL2  TNFα  GM-CSF   IFNγ  IL4  IL5  IL10  IL13   Pre-SCT   D2  D4   IL2  TNFα  GM-CSF   IFNγ  IL4  IL5  IL10   IL2  TNFα  GM-CSF   IFNγ  IL4  IL5  IL10  IL13   D5  D6   IL2  TNFα  GM-CSF   IFNγ  IL4  IL5  IL10  IL13   D7   GM-CSF  TNFα  IL2  IFNγ  IL4  IL5  IL10  IL13   D8  GM-CSF  TNFα  IL2  IFNγ  IL4  IL5  IL10  IL13   D3  GM-CSF  TNFα  IL2  IFNγ  IL4  IL5  IL10  IL13   IL2  TNFα  GM-CSF   IFNγ  IL4  IL5  IL10  IL13   D10  GM-CSF  TNFα  IL2  IFNγ  IL4  IL5  IL10  IL13   D9  GM-CSF  TNFα  IL2  IFNγ  IL4  IL5  IL10 Figure 3 . Cellular responses against KLH. Cryopreserved pre and postvaccine or pre and post-HSCT (pre-and post-SCT) PBMC samples from the indicated time points in the donors (D1-D10; a) and recipients (R2-R10; b) were tested in parallel for reactivity against KLH in a cytokine induction assay as described in the Materials and methods. Post-SCT samples at 4, 6, 7 and 9 months were obtained 1 month after the first, 2 months after the second, and 1 and 3 months after the third post-SCT vaccinations, respectively. Vaccination time points are indicated as V1, V2 and V3 in the donors (a) and recipients (b). KLH-specific cytokine production was calculated by subtracting cytokines produced by PBMC in the absence of antigen from that in the presence of KLH at each time point. KLH-specific cytokine production is presented as a heat map according to the scale shown.
host immunoglobulins. Indeed, polyreactive immune responses against Id were reported in Id vaccine studies, suggesting the presence of shared epitopes. [35] [36] [37] Finally, it should be noted that evaluation of immune responses in cryopreserved, compared with fresh PBMC, may have underestimated the immunogenicity of the vaccine in donors and recipients, and may explain why posttransplant anti-Id immune responses were observed in R3 (Figure 4c ) even though they were not detected in D3 (Supplementary Table 1 ). Nevertheless, following protocol treatment, all eight recipients that were assessable had detectable antibody or cellular responses, or both, to Id.
The increase in Tregs after vaccination in donors and recipients (Figures 6a and b) is also rather intriguing and may provide a possible explanation for the lower immunogenicity of Id. Although the increased Tregs in recipients may be part of normal immune reconstitution after HSCT, induction of Tregs by the Fc region of Id 38 or by shared epitopes 39 following vaccination may have contributed to increased Tregs in both donors and recipients. Post-60d Although we demonstrated that Id-specific immunity could be passively transferred in the early post-transplant setting, it remains unclear as to whether the infusion of lymphocytes from vaccinated donors at this time point results in optimal antitumor activity. Lymphocytes infused in the early posttransplant period are exposed to immunosuppressive agents such as calineurin inhibitors (for example, CYA) and antiproliferative agents (for example, MTX, mycophenolate mofetil), which are necessary to prevent GVHD. These agents may either blunt or eliminate antigen-specific lymphocytes. 40 As such, it may be necessary to infuse additional cells at later time points when the risk of GVHD is less or boost immune responses through post-transplant vaccinations. Indeed, based on recent studies that suggest the presence of high-levels of homeostatic cytokines (for example, IL-7, IL-15) after immune depletion, 41 it could be hypothesized that vaccinations earlier in the post-transplant setting may enhance the frequency of Id-and KLH-specific responses more than what was observed in our study.
In summary, our results provide proof of principle that cellular immunity induced against a model neoantigen (Figure 3b ) and tumor-specific antigen (Figures 4b-d) in the HSCT donors can be transferred to MM patients. This conclusion is important, because prior studies, including donor-derived Ig allotypes in recipients, largely investigated transfer of humoral immunity from donors to recipients. 25, 26 Second, donor-derived immunity could be boosted by recipient vaccination. The most definitive data was for boosting of humoral immunity (Figures 2c, d, h) ; although further increases of T cells was more variable. This variability may have been due to the fact that detection of antigen-specific T cells may be more sensitive to variables of compartmentalization (blood vs trafficking to tissues) and the timing of sample acquisition for immune response analysis (generally 4 weeks, rather than 2 weeks, after vaccination) may have not been optimal for detecting peak cytotoxic T-cell responses. A third, unexpected, conclusion was that this transferred donor-derived immunity can be detected relatively early after allotransplant, within the first 30 days, despite iatrogenic immunosuppression (GVHD prophylaxis), suggesting that for future trials it may be feasible to administer recipient booster vaccinations earlier than day 100. Finally, donor vaccination was associated with only transient, acceptable toxicity. These conclusions have been used to design and activate a subsequent randomized phase II trial of donor vaccination in MM with a primary clinical endpoint. þ T cells in donor postvaccine or recipient post-SCT groups compared with donor prevaccine group is indicated by an asterisk. P values were calculated by Wilcoxon signed-rank test. Post-HSCT samples at 4, 6, and 7 months were obtained 1 month after the first, 2 months after the second, and 1 month after the third post-SCT vaccination, respectively. KLH-specific CD4 þ T cells producing TNF-a or IL-2 were detected in seven of the eight evaluable recipients at 90 days post-SCT and in eight of the eight following post-transplant immunizations. 
